Meanwhile, trastuzumab binds to the HER2 extracellular domain IV, blocks the PI3K/AKT pathway, inhibits tumor cell proliferation, and the Fc segment of trastuzumab can also activate ADCC and induce apoptosis of tumor cells (66). Here, ERBB2 is linked to neoplasm.